Xeris Biopharma Holdings

NasdaqGS:XERS Stock Report

Mkt Cap: US$190.4m

Xeris Biopharma Holdings Future Growth

How is Xeris Biopharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


49.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGS:XERS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2024194-513114
12/31/2023152-73-37-334
12/31/2022108-102-65-754
9/30/202299-133-116-116N/A
6/30/202280-137-121-121N/A
3/31/202263-138-121-120N/A
12/31/202150-123-97-96N/A
9/30/202135-94-79-77N/A
6/30/202134-84-73-72N/A
3/31/202127-80-76-76N/A
12/31/202020-91-81-81N/A
9/30/202015-102-100-99N/A
6/30/20206-119-114-113N/A
3/31/20204-129-113-112N/A
12/31/20193-126-105-104N/A
9/30/20192-113-94-93N/A
6/30/20192-95-80-78N/A
3/31/20192-73-71-70N/A
12/31/20182-60-58-56N/A
9/30/20182-49-49-47N/A
6/30/20182-42-37-37N/A
3/31/20181-34-30-29N/A
12/31/20172-27-25-25N/A
12/31/20161-13-16-16N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XERS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XERS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XERS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XERS's revenue (26.6% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: XERS's revenue (26.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XERS's Return on Equity is forecast to be high in 3 years time


Discover growth companies